European Endocrinology最新文献_第10页

Is Continuous Glucose Monitoring Underappreciated in the UK? 持续血糖监测在英国被低估了吗?

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.76

Christopher G Parkin, Melissa Holloway, Jeffrey Truesdell, Tomas C Walker

{"title":"Is Continuous Glucose Monitoring Underappreciated in the UK?","authors":"Christopher G Parkin, Melissa Holloway, Jeffrey Truesdell, Tomas C Walker","doi":"10.17925/EE.2017.13.02.76","DOIUrl":"https://doi.org/10.17925/EE.2017.13.02.76","url":null,"abstract":"Introduction: Information about continuous glucose monitoring (CGM) use in the UK is limited. We conducted an online survey of a representative sample of current CGM users in England, Scotland and Wales to address this deficit.Methods: The 29-item online survey was conducted between 29 December 2016 and 25 January 2017. Persons with type 1 diabetes (T1D) and caregivers of T1D children/adolescents were recruited from mailing lists, using Nielsen and Harris Polling databases.Results: 315 patients and caregivers responded to the survey - 170 adult patients and 145 caregivers. Among respondents, 144 received full funding for CGM use, 72 received partial funding and 83 received no funding. Most reported improvements in glycated haemoglobin (HbA1c) (67.0%), fewer hypoglycaemia episodes (70.2%), improved hypoglycaemia awareness (77.5%) and better diabetes management (92.4%). Self-funders reported significantly higher CGM use (76.1%) than those who were fully funded (58.9%) and/or partially funded (65.9%), p=0.0008. Fewer than 50% of all respondents reported receiving guidance in interpreting CGM data from their diabetes care team; 30.1% of self-funders reported receiving no CGM support from their diabetes team compared with fully funded (2.8%) and partially funded (1.4%) respondents, p<0.0001.Conclusions: Patients with T1D and their caregivers are realising benefits from CGM use but are largely unsupported by the UK healthcare system.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 2","pages":"76-80"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7a/44/euendo-13-76.PMC5813469.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England. 英国伦敦西北部临床调试组对1型糖尿病患者持续血糖监测和低血糖认知受损的经济评价

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.81

Shraddha Chaugule, Nick Oliver, Brigitte Klinkenbijl, Claudia Graham

{"title":"An Economic Evaluation of Continuous Glucose Monitoring for People with Type 1 Diabetes and Impaired Awareness of Hypoglycaemia within North West London Clinical Commissioning Groups in England.","authors":"Shraddha Chaugule, Nick Oliver, Brigitte Klinkenbijl, Claudia Graham","doi":"10.17925/EE.2017.13.02.81","DOIUrl":"https://doi.org/10.17925/EE.2017.13.02.81","url":null,"abstract":"To assess the economic impact of providing real time continuous glucose monitoring (CGM) for people with type 1 diabetes (T1D) and impaired awareness of hypoglycaemia (IAH) within North West (NW) London clinical commissioning groups (CCGs).Methods: The eligible population for CGM and inputs for the economic budget impact model developed were derived from published data. The model includes cost of CGM; cost savings associated with lower hypoglycaemia related hospital admissions, accidents and emergency visits; self-monitoring of blood glucose (SMBG) strip usage; and glycated haemoglobin (HbA1c) reduction-related avoided complications and insulin pump use.Results: The cost of CGM for T1D-IAH (n=3,036) in the first year is £10,770,671 and in the fourth year is £11,329,095. The combined cost off-sets related to reduced hypoglycaemia admissions, SMBG strip usage and complications are £8,116,912 and £8,741,026 in years one and four, respectively. The net budget impact within the NW London CCGs is £2,653,760; £2,588,068 in years one and four respectively.Conclusions: Introduction of CGM for T1D-IAH patients will have a minimal budget impact on NW London CCGs, driven by cost of CGM and offsets from lower hypoglycaemia-related costs, reduced SMBG strip usage, avoided HbA1c-related complications and lower insulin pump use.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 2","pages":"81-85"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bd/f7/euendo-13-81.PMC5813470.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Antihyperglycemic Medications and Cardiovascular Risk Reduction. 降糖药物与降低心血管风险。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.86

Sarah L Anderson, Joel C Marrs

引用次数: 0

Beta-cell Insufficiency. β细胞功能不全。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.51

Sanjay Kalra, Yashdeep Gupta

引用次数: 2

The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration. 维格列汀的经验——诺华胰高血糖素样肽-1治疗项目启动25年，维格列汀首次注册10年。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.56

James E Foley, Bo Ahrén

{"title":"The Vildagliptin Experience - 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration.","authors":"James E Foley, Bo Ahrén","doi":"10.17925/EE.2017.13.02.56","DOIUrl":"https://doi.org/10.17925/EE.2017.13.02.56","url":null,"abstract":"The discovery of the incretin hormone glucagon like peptide-1 (GLP-1), and its usefulness in the treatment of type 2 diabetes mellitus (T2DM) followed by the finding that dipeptidyl peptidase-4 (DPP-4) inhibition prevents GLP-1 inactivation, led to the discovery of DPP-728. In 1999, studies with DPP-728 established the first proof-of-concept that DPP-4 inhibition improves glycaemic control in patients with T2DM. Further efforts to improve the binding kinetics of DPP-728 resulted in the discovery of vildagliptin (LAF237). In the last 20 years, a plethora of studies conducted by Novartis in collaboration with external investigators has demonstrated the mechanism of action of vildagliptin and its efficacy as monotherapy and as an add-on therapy for patients with T2DM. The studies establish that vildagliptin is a selective DPP-4 inhibitor that blocks GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) inactivation, thereby prolonging their action, resulting in improved glycaemic control. This review aims to discuss the discovery and development of vildagliptin, with an emphasis on mechanism of action and clinical efficacy.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 2","pages":"56-61"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.17925/EE.2017.13.02.56","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Call for Submissions. 征集作品。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.49

Abd Tahrani

引用次数: 0

Continuous Glucose Monitoring Adoption in the United Kingdom - An Economic and Policy Perspective. 持续血糖监测在英国的应用——从经济和政策的角度。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.73

Nick Oliver

引用次数: 5

Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes. 二肽基肽酶-4 抑制剂维达列汀的开发和授权后计划--优化 2 型糖尿病以外慢性疾病管理的临床证据。

European Endocrinology Pub Date : 2017-08-01 Epub Date: 2017-08-22 DOI: 10.17925/EE.2017.13.02.62

William David Strain, Päivi M Paldánius

{"title":"Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin - Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes.","authors":"William David Strain, Päivi M Paldánius","doi":"10.17925/EE.2017.13.02.62","DOIUrl":"10.17925/EE.2017.13.02.62","url":null,"abstract":"The last decade has witnessed the role of dipeptidyl peptidase-4 (DPP-4) inhibitors in producing a conceptual change in early management of type 2 diabetes mellitus (T2DM) by shifting emphasis from a gluco-centric approach to holistically treating underlying pathophysiological processes. DPP-4 inhibitors highlighted the importance of acknowledging hypoglycaemia and weight gain as barriers to optimised care in T2DM. These complications were an integral part of diabetes management before the introduction of DPP-4 inhibitors. During the development of DPP-4 inhibitors, regulatory requirements for introducing new agents underwent substantial changes, with increased emphasis on safety. This led to the systematic collection of adjudicated cardiovascular (CV) safety data, and, where 95% confidence of a lack of harm could not be demonstrated, the standardised CV safety studies. Furthermore, the growing awareness of the worldwide extent of T2DM demanded a more diverse approach to recruitment and participation in clinical trials. Finally, the global financial crisis placed a new awareness on the health economics of diabetes, which rapidly became the most expensive disease in the world. This review encompasses unique developments in the global landscape, and the role DPP-4 inhibitors, specifically vildagliptin, have played in research advancement and optimisation of diabetes care in a diverse population with T2DM worldwide.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 2","pages":"62-67"},"PeriodicalIF":0.0,"publicationDate":"2017-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ef/7b/euendo-13-62.PMC5813466.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989805","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine. 基于网络的术后放射性碘使用决策工具的初步研究。

European Endocrinology Pub Date : 2017-04-01 Epub Date: 2017-04-03 DOI: 10.17925/EE.2017.13.01.26

Shrujal S Baxi, Rachel Kurtzman, Anne Eaton, Eliza Dewey, Craig Bickford, Stephanie Fish, Leonard Wartofsky, R Michael Tuttle

{"title":"Pilot Study of a Web-based Decision Tool on Post-operative Use of Radioactive Iodine.","authors":"Shrujal S Baxi, Rachel Kurtzman, Anne Eaton, Eliza Dewey, Craig Bickford, Stephanie Fish, Leonard Wartofsky, R Michael Tuttle","doi":"10.17925/EE.2017.13.01.26","DOIUrl":"https://doi.org/10.17925/EE.2017.13.01.26","url":null,"abstract":"Background: The Thyroid Cancer Care Collaborative developed a web-based clinical decision-making module (CDMM) to inform risk-adjusted decisions on post-thyroidectomy radioactive iodine (RAI) use in papillary thyroid cancer (PTC). Methods: In a pilot study, we evaluated the CDMM in 19 PTC cases representing low- (five), intermediate- (seven) and high-risk (seven) disease. Two PTC experts and 10 PTC physicians reviewed cases and assigned risk level and RAI recommendation. The experts used a standard approach while the others used the CDMM. We assessed agreement between responses using a weighted Kappa. Results: Between experts, risk-assignment was concordant in 100%, 57% and 86% of low-, intermediate- and high-risk cases, respectively. Between CDMM users, risk-assignment was concordant in 100%, 29% and 14% in low-, intermediate- and high-risk cases, respectively (p=0.01). CDMM-assigned risk agreed with the expert-assigned risk in 100%, 25% and 0% of low-, intermediate- and high-risk cases, respectively (Kappa=0.69). For RAI use, the experts agreed in 15 cases while CDMM users agreed in eight. On further analysis, interpretation of extrathyroidal extension and lymph node staging led to discrepancies with the CDMM. Conclusions: For a web-based CDMM to accurately inform appropriate use of RAI in PTC, standard pathological and surgical reports are necessary.","PeriodicalId":38860,"journal":{"name":"European Endocrinology","volume":"13 1","pages":"26-29"},"PeriodicalIF":0.0,"publicationDate":"2017-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35989799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Progress and Problems in Bone and Mineral Disorders. 骨与矿物质疾病的研究进展与问题。

European Endocrinology Pub Date : 2017-04-01 Epub Date: 2017-04-03 DOI: 10.17925/EE.2017.13.01.19

Neil Gittoes

引用次数: 0